Results 131 to 140 of about 18,827 (200)

A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence. [PDF]

Cancers (Basel)
Pluard T, Grinda T, Dienstmann R, Thill M, Korytowsky B, Chen C, Portuhay S, Salvo-Halloran EM, Samjoo IA, Harbeck N.   +9 more
europepmc   +1 more source

Palbociclib in combination with dexamethasone, bortezomib, and doxorubicin for pediatric relapsed acute lymphoblastic leukemia. [PDF]

Blood Neoplasia
Srinivasan SG, Kamens JL, Marks LJ, Balagtas JMS, Rubnitz JE, Gruber TA.   +5 more
europepmc   +1 more source

Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models. [PDF]

J Transl Med
Villa M, Malighetti F, Villa AM, Cordani N, Aroldi A, Zambon A, Ramazzotti D, Mologni L.   +7 more
europepmc   +1 more source

Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue? [PDF]

Oncologist
Polwart C.
europepmc   +1 more source

Comparative safety signal prioritization of CDK4/6 inhibitors in breast cancer: a FAERS pharmacovigilance, machine learning, and clinical contextualization study. [PDF]

Front Pharmacol
Fan L, Liu S, Tang Y, Han X, Zhang Z, Su C, Sui Z, Zhao W.   +7 more
europepmc   +1 more source

<i>CDK4/6</i> Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions. [PDF]

Cancers (Basel)
Guan M, Hao H.
europepmc   +1 more source

Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary. [PDF]

Future Oncol
Rugo HS, Liu X, Li B, McRoy L, Chen C, Makari D, Layman RM, Brufsky A.   +7 more
europepmc   +1 more source

Assessing the utility of ctDNA as a prognostic marker in advanced ER-positive/HER2-negative breast cancer. [PDF]

Transl Cancer Res
Chaki M, Morrow C, Ahlgren H.
europepmc   +1 more source

Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial. [PDF]

Breast Cancer
Yamanaka T, Sohn J, Sudo K, Mukai H, Yamamoto N, Chung CF, Lu YS, Lee KH, Lee SC, Iwasa T, Iwata H, Watanabe K, Jung KH, Tanabe Y, Kang SY, Yasojima H, Aogi K, Tokunaga E, Sim SH, Yap YS, Matsumoto K, Tseng LM, Umeyama Y, Noguchi E, Hata T, Kuchiba A, Shibata T, Nakamura K, Fujiwara Y, Tamura K, Yonemori K.   +30 more
europepmc   +1 more source

A Pathway to Chordoma Treatment: A Review on CDKN2A and Therapeutic Targeting. [PDF]

Cancers (Basel)
Mohiuddin M, Vaca B, Haynal E, Bin-Alamer O, Zaki P, Abou-Al-Shaar H, Zenonos GA, Perez HA, Lopez-Gonzalez M, Gersey ZC.   +9 more
europepmc   +1 more source